Strategic Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,841
Closed -$504K 208
2022
Q4
$504K Sell
3,841
-254
-6% -$32.8K 0.11% 126
2022
Q3
$478K Sell
4,095
-22
-0.5% -$2.73K 0.11% 128
2022
Q2
$484K Buy
4,117
+375
+10% +$44.5K 0.1% 131
2022
Q1
$487K Buy
+3,742
New +$487K 0.08% 143

Other funds holding IBB

Strategic Advisors's IBB Position: Q1 2023 in Review

Strategic Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2023, closing a stake of 3,841 shares — an estimated $504K sold.

Strategic Advisors first reported a position in IBB in Q1 2022 and held it in 4 quarters. The position peaked at $504K in Q4 2022. 866 funds tracked by Wall St. Rank hold IBB as of Q1 2023.

  • Strategic Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2023 after selling out during the quarter.
  • Strategic Advisors sold 3,841 iShares Biotechnology ETF shares in Q1 2023, an estimated $504K.
  • Strategic Advisors first reported a position in iShares Biotechnology ETF in Q1 2022 and held it in 4 quarters.
  • Strategic Advisors's iShares Biotechnology ETF position peaked at $504K in Q4 2022.
  • 866 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2023.

Based on Strategic Advisors's 13F filing for Q1 2023, filed 27 Apr 2023.